Multiple myeloma is a malignant plasma cell disease that is often associated with multiple osteolytic damage, hypercalcemia, anemia, and renal damage. Due to the suppression of normal immunoglobulin production, it is prone to various infections. Chemotherapy is one of the common treatment modalities for multiple myeloma, and the frequently used regimen is the DVD regimen, which is composed of three drugs, liposomal adriamycin, vincristine, and dexamethasone. Liposomal adriamycin is administered as 9 mg/(m2.d) intravenously on days 1-4, vincristine 1.2 mg/m2 intravenously on day 1, and dexamethasone 40 mg/d intravenously or orally on days 1-4, 9-12, and 17-20, in 4-week courses. The current treatment of multiple myeloma are bortezomib-based chemotherapy regimens, such as VCD (bortezomib, cyclophosphamide, dexamethasone), VRD (bortezomib, lenalidomide, dexamethasone) regimens, such as poor results, and the current emergence of drugs such as CD38 monoclonal antibodies, which have better efficacy.